BR112019025611A2 - Derivados de xantina substituídos - Google Patents

Derivados de xantina substituídos

Info

Publication number
BR112019025611A2
BR112019025611A2 BR112019025611-3A BR112019025611A BR112019025611A2 BR 112019025611 A2 BR112019025611 A2 BR 112019025611A2 BR 112019025611 A BR112019025611 A BR 112019025611A BR 112019025611 A2 BR112019025611 A2 BR 112019025611A2
Authority
BR
Brazil
Prior art keywords
replaced
xanthine derivatives
derivatives
trpc5
therapy
Prior art date
Application number
BR112019025611-3A
Other languages
English (en)
Inventor
Gerlach Kai
Eickmeier Christian
Sauer Achim
Just Stefan
L. Chenard Bertrand
Original Assignee
Boehringer Ingelheim International Gmbh
Hydra Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Hydra Biosciences, Llc filed Critical Boehringer Ingelheim International Gmbh
Publication of BR112019025611A2 publication Critical patent/BR112019025611A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

a presente invenção refere-se a derivados de xantina substituídos, composições farmacêuticas contendo os mesmos e seu uso em terapia, particularmente no tratamento de condições tendo uma associação com trpc5 contendo canais iônicos.
BR112019025611-3A 2017-07-11 2018-07-06 Derivados de xantina substituídos BR112019025611A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180721.7 2017-07-11
EP17180721 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (1)

Publication Number Publication Date
BR112019025611A2 true BR112019025611A2 (pt) 2020-06-16

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025611-3A BR112019025611A2 (pt) 2017-07-11 2018-07-06 Derivados de xantina substituídos

Country Status (30)

Country Link
US (1) US10329292B2 (pt)
EP (1) EP3652176B1 (pt)
JP (1) JP7114702B2 (pt)
KR (1) KR20200030048A (pt)
CN (1) CN110997675B (pt)
AR (1) AR112448A1 (pt)
AU (1) AU2018299824B2 (pt)
BR (1) BR112019025611A2 (pt)
CA (1) CA3066922A1 (pt)
CL (1) CL2020000056A1 (pt)
CO (1) CO2019015102A2 (pt)
CY (1) CY1125014T1 (pt)
DK (1) DK3652176T3 (pt)
EA (1) EA039526B1 (pt)
ES (1) ES2903268T3 (pt)
HR (1) HRP20220029T1 (pt)
HU (1) HUE057600T2 (pt)
IL (1) IL271799B (pt)
LT (1) LT3652176T (pt)
MX (1) MX2020000402A (pt)
PH (1) PH12020500079A1 (pt)
PL (1) PL3652176T3 (pt)
PT (1) PT3652176T (pt)
RS (1) RS62826B1 (pt)
SA (1) SA519410851B1 (pt)
SG (1) SG11201912168TA (pt)
SI (1) SI3652176T1 (pt)
TW (1) TWI801398B (pt)
UA (1) UA124793C2 (pt)
WO (1) WO2019011802A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3894409B1 (en) * 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
CN113166151B (zh) * 2018-12-12 2023-12-01 勃林格殷格翰国际有限公司 经取代的黄嘌呤衍生物
KR20220079907A (ko) * 2019-10-04 2022-06-14 골드핀치 바이오 인코포레이티드 국소분절사구체경화증 및 당뇨병성 신장 질환의 바이오마커 기반 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2008010073A1 (en) * 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
CN105143229B (zh) * 2013-03-15 2017-06-30 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
JP6667093B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2016023831A1 (en) 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
JP6559228B2 (ja) 2014-09-17 2019-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物

Also Published As

Publication number Publication date
CN110997675A (zh) 2020-04-10
UA124793C2 (uk) 2021-11-17
TWI801398B (zh) 2023-05-11
HRP20220029T1 (hr) 2022-04-15
CA3066922A1 (en) 2019-01-17
MX2020000402A (es) 2020-08-17
PT3652176T (pt) 2022-01-13
US10329292B2 (en) 2019-06-25
AR112448A1 (es) 2019-10-30
IL271799A (en) 2020-02-27
DK3652176T3 (da) 2022-01-17
CO2019015102A2 (es) 2020-05-15
JP2020526591A (ja) 2020-08-31
AU2018299824B2 (en) 2022-06-16
CY1125014T1 (el) 2023-03-24
HUE057600T2 (hu) 2022-05-28
AU2018299824A1 (en) 2019-12-19
EA202090270A1 (ru) 2020-04-24
SI3652176T1 (sl) 2022-04-29
PH12020500079A1 (en) 2020-10-05
TW201908318A (zh) 2019-03-01
SG11201912168TA (en) 2020-01-30
SA519410851B1 (ar) 2023-02-26
PL3652176T3 (pl) 2022-04-04
EP3652176B1 (en) 2021-12-15
KR20200030048A (ko) 2020-03-19
IL271799B (en) 2022-08-01
EA039526B1 (ru) 2022-02-07
WO2019011802A1 (en) 2019-01-17
JP7114702B2 (ja) 2022-08-08
ES2903268T3 (es) 2022-03-31
EP3652176A1 (en) 2020-05-20
US20190016722A1 (en) 2019-01-17
CN110997675B (zh) 2022-06-07
CL2020000056A1 (es) 2020-06-12
RS62826B1 (sr) 2022-02-28
LT3652176T (lt) 2022-02-25

Similar Documents

Publication Publication Date Title
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112019005030A2 (pt) inibidores da interação de menina-llm
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112018016968A2 (pt) derivados de carboxamida úteis como inibidores de rsk
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
BR112017024719A2 (pt) compostos de hidroxil purina e seu uso
BR112018000568A2 (pt) antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]